Publications by authors named "Keith D Wilner"

Claim this Profile
F
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With -Positive Advanced NSCLC.
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, Jianying Zhou, Takashi Seto, Keith D Wilner

JTO Clin Res Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encorafenib plus binimetinib in patients with -mutant non-small cell lung cancer: phase II PHAROS study design.
Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Keith D Wilner

Future Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Vera Ehrenstein, Kui Huang, Johnny Kahlert, Shahram Bahmanyar, Pär Karlsson, Keith D Wilner

Pharmacoepidemiol Drug Saf· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Keith D Wilner

J Thorac Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
Allison Magnuson, Suanna S Bruinooge, Harpreet Singh, Keith D Wilner, Shadia Jalal

Clin Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Ying Cheng, Tony S Mok, Xiangdong Zhou, Shun Lu, Qing Zhou, Keith D Wilner

Lung Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Tony S Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Keith D Wilner

Drugs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Kazuhiko Nakagawa, Koichi Matsumura, Tayler Scory, Megan S Farris, Kelly A Larkin-Kaiser, Keith D Wilner

Future Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
MeganS Farris, Kelly A Larkin-Kaiser, Tayler Scory, Devon Boyne, Keith D Wilner

Future Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
Benjamin J Solomon, Elizabeth E Kim, Maria Winter, Katherine Monti, Yiyun Tang, Keith D Wilner

Lung Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe.
Kui Huang, Terri Madison, Beatrice Wehler, Marcello Tiseo, Keith D Wilner

Pharmacol Res Perspect· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Jeffrey W Clark, D Ross Camidge, Eunice L Kwak, Robert G Maki, Geoffrey I Shapiro, Keith D Wilner

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Keith D Wilner

Nat Med· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and network meta-analysis of first-line therapy for advanced -positive non-small-cell lung cancer.
Jacob Franek, Joseph C Cappelleri, Kelly A Larkin-Kaiser, Keith D Wilner, Rickard Sandin

Future Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.
Swan Lin, Dana J Nickens, Maulik Patel, Keith D Wilner, Weiwei Tan

Cancer Chemother Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
D Ross Camidge, Elizabeth E Kim, Tiziana Usari, Anna Polli, Iona Lewis, Keith D Wilner

J Thorac Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.
Keith D Wilner, Tiziana Usari, Anna Polli, Elizabeth E Kim

Future Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
Yi-Long Wu, Shun Lu, You Lu, Jianying Zhou, Yuan-Kai Shi, Keith D Wilner

J Thorac Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Keith D Wilner

J Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J Solomon, Keith D Wilner

Cancer Res Treat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Keith D Wilner

J Clin Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Chandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, Xin Huang, Dongrui R Lu, Keith D Wilner

Anticancer Drugs· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.
Ken Y Yoneda, Judith R Scranton, Michael A Cadogan, Vanessa Tassell, Sashi Nadanaciva, Keith D Wilner

Clin Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.
Fiona Blackhall, D Ross Camidge, Alice T Shaw, Jean-Charles Soria, Benjamin J Solomon, Keith D Wilner

ESMO Open· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.
Erjian Wang, Dana J Nickens, Akintunde Bello, Reza Khosravan, Michael Amantea, Keith D Wilner

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis